Phase 2 N=97 Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
Esophageal Cancer · Gastric Cancer
Primary: Pathologic Complete Response Rate — 15.4; 16.7 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=94 Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Proportion of Patients With Objective Response Evaluated by RECIST (Solid Tumor Response Criteria) — 0.045; 0.07 Proportion of participants
Phase 2 N=30 Faslodex in McCune-Albright Syndrome
Puberty, Precocious · McCune-Albright Syndrome
Primary: Change in Frequency of Annualized Days of Vaginal Bleeding on Treatment Compared to Baseline — -3.6 Days per year
Phase 2 N=991 Efficacy Study of the Non-Pneumatic Anti-Shock Garment (NASG) in Egypt
Hypovolemic Shock · Hemorrhage
Primary: Extreme Adverse Outcomes (EAO) - a Combined Outcome of Maternal Mortality or Severe Morbidity (Cardiac,Respiratory, Renal or Cerebral Dysfunction) — 27; 11 participants…
Phase 2 N=21 Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Number of Participants Who Remained Free of Progression at the 27th Week. — 21 participants — p=0.0006
Phase 2 N=95 Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
Adult Acute Basophilic Leukemia · Adult Acute Eosinophilic Leukemia · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Number of Participants With Complete Response — 61; 9 Participants
Phase 2 N=27 A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)
Advanced Cancer
Primary: Percent of Participants With a Serious Drug-related Adverse Event (AE) — 7.7; 0; 0; 0 percent of participants
Phase 2 N=177 Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant
Major Depressive Disorder
Primary: Change From Augmentation Baseline for Non-Remitters in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score at Week 6 - Last Observation Carried Forward (LOCF)…
Phase 2 N=30 Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater
Gastrointestinal Cancer
Primary: Number of Participants With Overall Response — 3; 12 participants
Phase 2 N=120 Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults >= 65 Years of Age
Influenza
Primary: Number of Participants With Local and Systemic Immediate Reactogenicity Complaints — 0; 0; 0; 0 Participants
Phase 2 N=19 Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer
Breast Cancer
Primary: Number of Participants With Tumor Response — 5; 9; 1; 3 participants
Phase 2 N=109 A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)
Diabetic Retinopathy
Primary: Change in Central Subfield Retinal Thickness From Baseline Over All Study Visits — 21; -35; -86; -3 microns — p=0.009
Phase 2 N=474 A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years
Influenza · Swine-origin A/H1N1 Influenza
Primary: Number of Participants With Antibody Titers ≥ 10 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 6 to 35 Months — 5; 2; 0; 72 Participants
Phase 2 N=34 Phase II 5-Azacytidine Plus VPA Plus ATRA
Myelodysplastic Syndrome · Acute Myelogenous Leukemia
Primary: Number of Participants With Response — 12; 3; 7 Participants
Phase 2 N=849 A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly
Influenza · Swine-origin A/H1N1 Influenza
Primary: Number of Participants With Antibody Titers ≥ 10 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 18 to 64 Years — 69; 70; 61; 23 Participants